Cabotegravir demonstrated efficacy as a long-acting PrEP, with no new HIV cases in the PILLAR trial over 12 months. The combination of cabotegravir and rilpivirine showed high viral suppression rates ...
The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...
Even under the best of circumstances, remembering to take a daily pill can be a challenge. For someone living with schizophrenia, it can be especially difficult. That’s because schizophrenia affects ...
Long-acting injectable formulations are designed to maintain therapeutic drug concentrations over extended periods—from weeks to months—following a single administration. By forming a depot at the ...
DENVER -- The combination injectable cabotegravir-rilpivirine (CAB-RPV; Cabenuva) safely maintained long-term viral suppression among adolescents with HIV who switched from daily oral medications, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results